

- 1997; 1-40
70. Ray MB, Mendenhall CL, French SW, Gartside PS: Bile duct changes in alcoholic liver disease. The Veterans Administration Cooperative Study Group. *Liver* 1993; 13: 36-45
  71. Hsia CC, Evarts RP, Nakatsukasa H, Marsden ER, Thorgerisson SS: Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. *Hepatology* 1992; 16: 1327-1333
  72. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK: Oval cell numbers in human chronic liver diseases are directly related to disease severity. *Am J Pathol* 1999; 154: 537-541
  73. Britton RS, Edling JE, Grisham MB, Bacon BR: Hepatic DNA damage in rats with chronic dietary iron overload. *Hepatology* 1991; 21: 4
  74. Nordenson I, Ritter B, Beckman A, Beckman L: Idiopathic hemochromatosis and chromosomal damage. *Hum Hered* 1992; 42: 143-145
  75. Gonzalez-Peralta RP, Davis GL, Lau JY: Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. *J Hepatol* 1994; 21: 255-259
  76. Mondelli MU, Cerino A, Bellotti V, de Koning A: Immunobiology and pathogenesis of hepatitis C virus infection. *Res Virol* 1993; 144: 269-274
  77. Cerny A, Chisari FV: Immunological aspects of HCV infection. *Intervirology* 1994; 37: 119-125
  78. Sherman KE, O'Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, Wilber J: Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. *J Clin Microbiol* 1993; 31: 2679-2682
  79. Horvath J, Raffanti SP: Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. *Clin Infect Dis* 1994; 18: 339-347
  80. Senba M, Nakamura T, Itakura H: Statistical analysis of relationship between iron accumulation and hepatitis B surface antigen. *Am J Clin Pathol* 1985; 84: 340-342
  81. Bullen JJ, Spalding PB, Ward CG, Gutteridge JM: Hemochromatosis, iron and septicemia caused by *Vibrio vulnificus*. *Arch Intern Med* 1991; 151: 1606-1609
  82. Good MF, Powell LW, Halliday JW: Iron status and cellular immune competence. *Blood Rev* 1988; 2: 43-49
  83. Good MF, Chapman DE, Powell LW, Halliday JW: The effect of experimental iron-overload on splenic T cell function: analysis using cloning techniques. *Clin Exp Immunol* 1987; 68: 375-383
  84. Gascon P, Zoumbos NC, Young NS: Immunologic abnormalities in patients receiving multiple blood transfusions. *Ann Intern Med* 1984; 100: 173-177
  85. Kaplan J, Sarnaik S, Gitlin J, Lusher J: Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. *Blood* 1984; 64: 308-310
  86. Akbar AN, Fitzgerald-Bocarsly PA, de Sousa M, Giardina PJ, Hilgartner MW, Grady RW: Decreased natural killer activity in thalassemia major: a possible consequence of iron overload. *J Immunol* 1986; 136: 1635-1640
  87. Matzner Y, Hershko C, Polliack A, Konijn AM, Izak G: Suppressive effect of ferritin on *in vitro* lymphocyte function. *Br J Haematol* 1979; 42: 345-353
  88. Harada T, Baba M, Torii I, Morikawa S: Ferritin selectively suppresses delayed-type hypersensitivity responses at induction or effector phase. *Cell Immunol* 1987; 109: 75-88
  89. Pattanapanyasat K, Hoy TG, Jacobs A: The response of intracellular and surface ferritin after T-cell stimulation *in vitro*. *Clin Sci* 1987; 73: 605-611
  90. Konijn AM, Meyron-Holtz EG, Levy R, Ben-Bassat H, Matzner Y: Specific binding of placental acidic isoferritin to cells of the T-cell line HD-MAR. *FEBS Lett* 1990; 263: 229-232
  91. Moss D, Powell LW, Arosio P, Halliday JW: Characterization of the ferritin receptors of human T lymphoid (MOLT-4) cells. *J Lab Clin Med* 1992; 119: 273-279
  92. Chelbi-Alix MK, Thang MN: Multiple molecular forms of interferon display different specific activities in the induction of the antiviral state and 2'5' oligoadenylate synthetase. *Biochem Biophys Res Commun* 1986; 141: 1042-1050
  93. Bacon BR, Fried MW, DiBisceglie AM: A 39-year-old man with chronic hepatitis, elevated serum ferritin values, and a family history of hemochromatosis. *Semin Liver Dis* 1993; 13: 101-105
  94. Ward RJ, O'Connell MJ, Dickson DP, Reid NM, Wade VJ, Mann S, Bomford A, Peters TJ: Biochemical studies of the iron cores and polypeptide shells of haemosiderin isolated from patients with primary or secondary haemochromatosis. *Biochim Biophys Acta* 1989; 993: 131-133
  95. van Asbeck BS, Verbrugh HA, van Oost BA, Marx JJ, Imhof HW, Verhoef J: *Listeria monocytogenes* meningitis and decreased phagocytosis associated with iron overload. *Br Med J (Clin Res Ed)* 1982; 284: 542-544
  96. van Asbeck BS, Marx JJ, Struyvenberg A, Verhoef J: Functional defects in phagocytic cells from patients with iron overload. *J Infect* 1984; 8: 232-240
  97. Ballart IJ, Estevez ME, Sen L, Diez RA, Giuntoli J, de Miani SA, Penalver J: Progressive dysfunction of monocytes associated with iron overload and age in patients with thalassemia major. *Blood* 1986; 67: 105-109
  98. Olynyk J, Clarke SL: Functional heterogeneity of Kupffer cells in iron overload. *Hepatology* 1998; 28: 441A
  99. Van Thiel DH, Friedlander L, Molloy PJ, Kania RJ, Fagioli S, Wright HI, Gasbarrini A, Caraceni P: Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. *Hepatogastroenterology* 1996; 43: 1557-1561
  100. Bayraktar Y, Koseoglu T, Kayhan B, Uzunalimoglu B, Gurakar A, Van Thiel DH: The use of desferrioxamine infusions to enhance the response rate to interferon  $\alpha$  (IFN) treatment of chronic viral hepatitis. *Gastroenterology* 1995; 108 (4 Suppl): A1031
  101. Kugelmas M, Lieberman BY, Carey WD: Deironization in chronic hepatitis C patients previously non-responsive to interferon improves transaminases but not viral activity. *Gastroenterology* 1995; 108 (4 Suppl): A1104
  102. Yano M, Kakumu S, Hayashi H, Takikawa T, Nishimura N: Phlebotomy followed by  $\alpha$ -interferon therapy in patients with chronic hepatitis C. *Hepatology* 1995; 22: 119A
  103. Tsai NC, Zuckerman E, Han SH, Goad K, Redeker AG, Fong TL: Effect of iron depletion on long-term response to interferon- $\alpha$  in patients with chronic hepatitis C who previously did not respond to interferon therapy. *Am J Gastroenterol* 1997; 92: 1831-1834